With a new study in the journal Science Bulletin, researchers at Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University have ...

As of Friday, January 09, Coherus Oncology, Inc.’s CHRS share price has surged by 6.86%, which has investors questioning if ...

AI Foundation Model for Tumor and Immune Biology to Guide Precision Patient Selection for Novel Bifunctional OTP-01 BostonGene, the developer of the leading AI foundation model for tumor and immune ...

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Dec. 28, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company ...

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced that it has ...

BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited ("Ottimo"), an innovative, ...

As of Wednesday, January 07, CytomX Therapeutics, Inc.’s CTMX share price has surged by 6.40%, which has investors questioning if this is right time to sell.

Successfully completed meeting with FDA to align on and enable outpatient dosing of systemic lupus erythematosus (SLE) and lupus nephritis (LN) patients with prulacabtagene leucel (prula-cel, formerly ...

Harbour BioMed inks long-term strategic collaboration with Lannacheng to advance next-generation radionuclide drug conjugates: Shanghai, China Tuesday, December 30, 2025, 13:00 Hr ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.